Association of Elevated Fibrinogen and C-Reactive Protein Levels with Carotid Lesions in Patients with Newly Diagnosed Hypertension or Type II Diabetes

Archives of Medical Research

Volumn 37, Issue 8, 2006, Pages 1004-1009

  Corrado, Egle ^a   Rizzo, Manfredi ^b   Muratori, Ida ^b   Coppola, Giuseppe ^a   Novo, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; C reactive protein; Events; Hypertension; Inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GENDER; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MODULATION; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALIDITY; PROPHYLAXIS; PROTEIN BLOOD LEVEL; SMOKING; STATISTICAL ANALYSIS;

EID: 33749434265     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.06.005     Document Type: Article

References (41)

1. Corrado E., and Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg 105 (2005) 567-579
2. Acevedo M., Foody J.M., Pearce G.L., and Sprecher D.L. Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J 143 (2002) 277-282
3. Folsom A.R., Aleksic N., Catellier D., Folsom A.R., Aleksic N., and Catellier D. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 144 (2002) 233-238
4. Mazoyer E., Drouet L., Soria C., Fruchard J.C., Pellerin A., Arcan J.C., et al. Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude. Thromb Res 95 (1999) 163-176
5. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
6. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
7. Pearson T., Mensah G., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
8. Engstrom G., Lind P., Hedblad B., Stavenow L., Janzon L., and Lindgarde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 33 (2002) 2744-2749
9. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 5 (2005) 309-322
10. Corrado E., Rizzo M., Tantillo R., Muratori I., Bonura F., Vitale G., et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5 year follow-up study. Stroke 37 (2006) 482-486
11. Magyar M.T., Szikszai Z., Balla J., Valikovics A., Kappelmayer J., Imre S., et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 34 (2003) 58-63
12. Hashimoto H., Kitagawa K., Hougaku H., Shimizu Y., Sakaguchi M., Nagay Y., et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104 (2001) 63-67
13. Sellmayer A., Limmert T., and Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment. Int Angiol 22 (2003) 15-23
14. Hashimoto H., Kitagawa K., Hougaku H., Etani H., and Hori M. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35 (2004) 1625-1630
15. Coppola G., Corrado E., Muratori I., Tantillo R., Vitale G., Lo Coco L., et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 106 (2006) 16-20
16. Murata M., and Ide T. Determination of cholesterol in sub-nanomolar quantities in biological fluids by high-performance liquid chromatography. J Chromatogr 579 (1992) 329-333
17. Montagne P., Laroche P., Cuilliere M.L., Varcin P., and Duheille J. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal 1 (1992) 24-29
18. Myers G.L., Rifai N., Tracy R., Roberts W.L., Alexander R.W., Biasucci L., et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group. Circulation 110 (2004) 577-578
19. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17 (1957) 231-237
20. Imperatore G., Riccardi G., Iovine C., Rivallese A., and Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 21 (1998) 649-654
21. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
22. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
23. Pasceri V., Chang J., Willerson J.T., and Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
24. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
25. Levenson J., Giral P., Razavian M., Gariepy J., and Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 15 (1995) 1263-1268
26. Becker R.C., Cannon C.P., Bovill E.G., Tracy R.P., Thompson B., Knatterud G.L., et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 78 (1996) 142-147
27. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tiblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
28. Woodward M., Lowe G.D., Rumley A., Tunstall-Pedoe H., Philippou H., Lane D.A., et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 97 (1997) 785-797
29. Maresca G., Di Blasio A., Marchioli R., and Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol 19 (1999) 1368-1377
30. Bautista L.E., Lopez-Jaramillo P., Vera L.M., Casas J.P., Otero A.P., and Guaracao A.I. Is C-reactive protein an independent risk factor for essential hypertension?. J Hypertens 19 (2001) 857-861
31. Jager A., van Hinsbergh V.W., Kostense P.J., Emeis J.J., Nijpels G., Dekker J.M., et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 22 (2002) 593-598
32. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson Jr. S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
33. Burke G.L., Evans G.W., Riley W.A., Sharrett A.R., Howard G., Barnes R.W., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26 (1995) 386-391
34. Bots M.L., Moons K.G., Hollander M., Hoffman A., Koudstaal P.J., Grobbee D.E., et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circulation 96 (1997) 1432-1437
35. Greenland P., Smith S.C., and Grundy S.M. Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104 (2001) 1863-1867
36. Bard R.L., Kalsi H., Rubenfire M.D., and Brook R.D. Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol 93 (2004) 1030-1032
37. Rizzo M., Barbagallo C.M., Severino M., Polizzi F., Onorato F., Noto D., et al. Low-density-lipoprotein peak particle size in a Mediterranean population. Eur J Clin Invest 33 (2003) 126-133
38. Ridker P., Rifai N., Pfeffer M., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
39. Jialal D., Stein D., Balis D., Grundy S., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
40. Atalar E., Ozmen F., Haznedaroglu I., Acil T., Ozer N., Ovunc K., et al. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int J Cardiol 84 (2002) 227-231
41. Papadakis J.A., Ganotakis E.S., Jagroop I.A., Winder A.F., and Mikhailidis D.P. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 69 (1999) 237-244